{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:04:29Z","timestamp":1782299069663,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"publisher","award":["2173"],"award-info":[{"award-number":["2173"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jiph.2025.102676","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T15:18:42Z","timestamp":1737299922000},"page":"102676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses"],"prefix":"10.1016","volume":"18","author":[{"given":"Fatemeh","family":"Ashrafian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Salehi-Vaziri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Mostafavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiedeh Haji","family":"Maghsoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dahmardeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Bavand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parinaz","family":"Tajmehrabi Namini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsan","family":"Zali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Tahmasebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Sadat Larijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3502-8524","authenticated-orcid":false,"given":"Amitis","family":"Ramezani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jiph.2025.102676_bib1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.cmi.2021.11.010","article-title":"Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study","volume":"28","author":"Chia","year":"2022","journal-title":"Clin Microbiol Infect: Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jiph.2025.102676_bib2","doi-asserted-by":"crossref","unstructured":"Eybpoosh S, Biglari A, Sorouri R, Ashrafian F, Sadat Larijani M, Verez-Bencomo V, Toledo-Romani ME, Valenzuela Silva C, Salehi-Vaziri M, Dahmardeh S, Doroud D, Banifazl M, Mostafavi E, Bavand A, Ramezani A. Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals PLoS Pathog 19 11 e1011744 https:\/\/doi.org\/10.1371\/journal.ppat.1011744","DOI":"10.1371\/journal.ppat.1011744"},{"issue":"1","key":"10.1016\/j.jiph.2025.102676_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2023.12.1.1","article-title":"Exploring the experience of developing COVID-19 vaccines in Iran","volume":"12","author":"Ghanei","year":"2023","journal-title":"Clin Exp Vaccin Res"},{"issue":"1","key":"10.1016\/j.jiph.2025.102676_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13337-022-00755-1","article-title":"A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges","volume":"33","author":"Rahman","year":"2022","journal-title":"Virusdisease"},{"key":"10.1016\/j.jiph.2025.102676_bib5","unstructured":"COVID-19 medicines [Internet]. European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines. [Published date: 2022, Feb. Accessed date: 2024, Jan]."},{"key":"10.1016\/j.jiph.2025.102676_bib6","unstructured":"COVID-19 Vaccines [Internet]. U.S. Departmen of Health and Human Services Available from: https:\/\/www.hhs.gov\/coronavirus\/covid-19-vaccines\/index.html. [Accessed date: 2024, Apr]."},{"issue":"10","key":"10.1016\/j.jiph.2025.102676_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20555","article-title":"Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine","volume":"9","author":"Farahmand","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jiph.2025.102676_bib8","article-title":"Vaccine breakthrough infection with the SARS-CoV-2 delta or omicron (BA.1) variant leads to distinct profiles of neutralizing antibody responses","author":"Seaman","year":"2022","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.jiph.2025.102676_bib9","first-page":"838","article-title":"SARS-CoV-2 Omicron variant: characteristics and prevention","volume":"2","author":"He","year":"2021","journal-title":"Med Sci J"},{"issue":"44","key":"10.1016\/j.jiph.2025.102676_bib10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.15585\/mmwr.mm7044e2","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendations for additional primary and booster doses of COVID-19 vaccines\u2014United States, 2021","volume":"70","author":"Mbaeyi","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jiph.2025.102676_bib11","unstructured":"Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States [Internet]. Centers for Disease Control and Prevention (CDC). Available from: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html. [Published date: 2023,Dec. Accessed date: 2024, Jun.]."},{"issue":"4","key":"10.1016\/j.jiph.2025.102676_bib12","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41591-022-01699-1","article-title":"Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jiph.2025.102676_bib13","article-title":"Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults","author":"Demonbreun","year":"2021","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.jiph.2025.102676_bib14","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1038\/s41598-023-35147-y","article-title":"PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals","volume":"13","author":"Ramezani","year":"2023","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jiph.2025.102676_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11081376","article-title":"A comparative study of immunogenicity, antibody persistence, and safety of three different COVID-19 boosters between individuals with comorbidities and the normal population","volume":"11","author":"Ashrafian","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.jiph.2025.102676_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.896151","article-title":"Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine\u2013a prospective observational study","volume":"13","author":"Herzberg","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jiph.2025.102676_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11071184","article-title":"SARS-CoV-2 antibody dynamics after COVID-19 vaccination and infection: a real-world cross-sectional analysis","volume":"11","author":"Yorsaeng","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.jiph.2025.102676_bib18","unstructured":"WHO. WHO COVID-19 dashboard 2023. Available from: https:\/\/data.who.int\/dashboards\/covid19\/vaccines19. [Published date: 2020,July. Accessed date: 2024, Jan]."},{"issue":"1","key":"10.1016\/j.jiph.2025.102676_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-77331-8","article-title":"Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects","volume":"14","author":"Doroud","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jiph.2025.102676_bib20","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jiph.2025.102676_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28164","article-title":"Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster","volume":"95","author":"Favresse","year":"2023","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.jiph.2025.102676_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/vaccines10020331","article-title":"SARS-CoV-2 spike and neutralizing antibody kinetics 90 days after three doses of BNT162b2 mRNA COVID-19 vaccine in Singapore","volume":"10","author":"Lau","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.jiph.2025.102676_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2022.100180","article-title":"Breakthrough infections after COVID-19 vaccination: insights, perspectives and challenges","volume":"14","author":"Amanatidou","year":"2022","journal-title":"Metab Open"},{"issue":"14","key":"10.1016\/j.jiph.2025.102676_bib24","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJMc2202542","article-title":"Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron","volume":"386","author":"Regev-Yochay","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jiph.2025.102676_bib25","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a fourth dose of BNT162b2 against Omicron in Israel","volume":"386","author":"Bar-On","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiph.2025.102676_bib26","unstructured":"Three Years After Covid-19 Vaccine Rollout, CDC Still Gets Messaging Wrong [Internet]. Forbes. 2023 [cited 25 Dec, 2023]. Available from: \u3008https:\/\/www.forbes.com\/sites\/joshuacohen\/2023\/12\/13\/three-years-after-covid-19-vaccine-rollout-cdc-still-gets-messaging-wrong\/?sh=\u20096bc52d831178\u3009."},{"key":"10.1016\/j.jiph.2025.102676_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2022.05.026","article-title":"Long-term serological SARS-CoV-2 IgG kinetics following mRNA COVID-19 vaccine: real-world data from a large cohort of healthcare workers","volume":"122","author":"Oliveira-Silva","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiph.2025.102676_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786554","article-title":"Response and duration of serum anti-SARS-CoV-2 antibodies after inactivated vaccination within 160 days","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.jiph.2025.102676_bib29","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3390\/vaccines11071184","article-title":"SARS-CoV-2 antibody dynamics after COVID-19 vaccination and infection: a real-world cross-sectional analysis","volume":"11","author":"Yorsaeng","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.jiph.2025.102676_bib30","article-title":"Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh","volume":"14","author":"Haq","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jiph.2025.102676_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41422-021-00590-x","article-title":"Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern","volume":"32","author":"Ai","year":"2022","journal-title":"Cell Res"},{"issue":"8","key":"10.1016\/j.jiph.2025.102676_bib32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S1473-3099(22)00271-7","volume":"22","author":"Munro","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jiph.2025.102676_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102231","article-title":"Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial","volume":"64","author":"Liu","year":"2023","journal-title":"Eclinicalmedicine"},{"issue":"3","key":"10.1016\/j.jiph.2025.102676_bib34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3390\/vaccines11030570","article-title":"The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: safety and immunogenicity to Omicron BA. 4\/BA. 5","volume":"11","author":"Kanokudom","year":"2023","journal-title":"Vaccines"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034125000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:17:50Z","timestamp":1741115870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034125000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1876034125000255"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102676","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2025.102676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}],"article-number":"102676"}}